Eli Lilly launches Mounjaro KwikPen in India, expanding weight-loss drug options and intensifying competition with Novo Nordisk.

Eli Lilly and Company's recovery has not regained fervor as the digestion over its high-growth premium continues. Learn more about LLY stock here.

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s ...

The latest trading day saw Eli Lilly (LLY) settling at $770.64, representing a +1.04% change from its previous close.

Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts.

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its “Buy” rating on Eli Lilly stock.

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new challenger to blockbusters from Novo Nordisk A/S and Eli Lilly & Co.

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly LLY in the last three months. The table below offers a condensed view of their ...

Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with ...

There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk. One drug I've been keeping a close eye on ...

With detailed readouts from a suite of late-stage trials now on tap, Eli Lilly is heading to regulators in pursuit of a green light for its once-a-week insulin asset efsitora alfa.